All News

PsA, PSO, nail

Two Year Guselkumab Benefits in Psoriatic Arthritis

d MedPage Today

Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.

Read Article
CV,risk,MI,heart,cardiac

CV Risk Management in Rheumatic Disease Patients

d Jack Cush, MD

The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.

Read Article
Pills.men_.jpg

Rheumatoid Arthritis Nonadherence is Multifactorial

d Jack Cush, MD

The consequences of medication non-adherence (NA) in rheumatoid arthritis (RA) care are numerous and damaging.  A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clini

Read Article
We have an exciting agenda for #RNL2022, with topics ranging from Psoriatic Disease for Rheumatologists to Advances in Psoriasis Management and speakers from around the world, including Dr. Bruce Strober. Register Today! https://t.co/VZ2hmxAmDw https://t.co/AJbSLNXDql

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr Virginia Steen at #RWCS2022. On scleroderma lung Dz that worsens outcomes https://t.co/n7IV8UVI2N https://t.co/kLmiKiseur
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid Arthritis Nonadherence is Multifactorial A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clinical factors. https://t.co/FWamPS2fTQ https://t.co/EtoStfdTsI

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman presents on paraneoplastic syndromes. Many autoantibodies have been possibly implicated. #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/xx54hAKY3C
Dr. John Cush RheumNow ( View Tweet)
1st approved Rx for neuromyelitis optical (Device syndr). Eculizumab, C5a inhibitor, weird effective at preventing relapses of NMO #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/a6LyTi3LXL
Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman presents treatment of Stiff Man syndrome why muscle relaxants, benzos, IVIG?? Poor outcomes nevertheless #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/xDXJCM34aO
Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman presents on rare Stiff Man syndrome at #RWCS2022 https://t.co/n7IV8UVI2N
Dr. John Cush RheumNow ( View Tweet)
EMA has posted its intent to review the safety of JAK inhibitors used to treat several chronic inflammatory disorders (RA, PsA, JIA, AS, UC, atopic dermatitis) based on the release of the Pfizer tofacitinib A3921133 study https://t.co/loG7zWBWHs

Links:

Dr. John Cush RheumNow ( View Tweet)

Mortality of Cryoglogulinemia has declined between 1999 and 2018 freom 0.4 deaths per million to 0.19. Cryo found in 39% of HCV(2009–2013) down to 26% (2014–2018). Prevalence and deaths dropped witn introduction of HCV antiviral Rx https://t.co/h9rL1ftI0n

Links:

Dr. John Cush RheumNow ( View Tweet)

Challenges in Lupus: -Mortality greatest in 1st yr -Dx Delays 6.4 yrs -Long-term complications increased 50 fold -Steroids worsen long-term outcomes -Health care costs increased 3 to 5 years prior to Dx -Mean delay in drug starts after Dx =177 days https://t.co/QUbsIQtcRa https://t.co/zAMUp99ecg

Links:

Dr. John Cush RheumNow ( View Tweet)
Olumiant (baricitinib) studies in Lupus halted by Lilly due to mixed results in phase 3 trials. While the BRAVE-1 study showed 4-mg BARI meeting primary endpoint at 52 weeks; the Brave-II failed to do same & failed key secondary endpoints https://t.co/XBmo15UCYl

Links:

Dr. John Cush RheumNow ( View Tweet)

Lupus international cohort study of 1460 HCQ pts showed that SLE flares were increased with dose reduction (aHRs 1.20;CI 1.04 to 1.38) and HCQ discontinuation (aHR 1.56; 1.31 to 1.86), higher with low educational levels after HCQ D/C https://t.co/fO4fBtrFYo

Links:

Dr. John Cush RheumNow ( View Tweet)

Fatigue in Early RA registry - study of n = 1236 pts w/ Dz duration 11 mos. The prevalence rates of fatigue was 44% and severe fatigue 19% and was stable over 3 yrs. Greater fatigue in women, high pain, mental Dz, function; BUT NOT SJC or ESR https://t.co/hEgPbsAqYZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Taiwan study of 12,786 pre-dialysis advanced CKD patients with gout shows that use of febuxostat or allopurinol was assoc w/ a reduced sepsis/infection risk - most w/ FEB (HR, 0.68; 0.52–0.87), but no signif difference in MACE or CVA https://t.co/zp7JLwzah8

Links:

Dr. John Cush RheumNow ( View Tweet)

Join Dr. Ronan Kavanagh for an incredible STEP Session at #RNL2022, where he will discuss The Jazz of Rheumatology. Register today! https://t.co/hMzdpN327q https://t.co/uHYC9VV1kp

Links:

Dr. John Cush RheumNow ( View Tweet)
Round up of last week's QD Clinics: -Steroid Weaning -Diagnosing Neuropsychiatric Lupus - Not the Same Ol’ Lecture - Your Next Follow-up Visit is When? QD Clinic is sponsored by RheumNow Live https://t.co/9U1wcbIMs4 https://t.co/HjyyGtbe4r

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Biobank case control study of 15 871 pts with Gout and COVID. Gout associated with diagnosis of COVID-19 (OR 1·20; CI 1·11–1·29) but not with risk of COVID-19-related death in the cohort of patients diagnosed with COVID-19 (1·20, 0·96–1·51). https://t.co/dN5YnIqhzD

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×